PortalPublikationenCatheter ablation of stable ventricular tachycardia before d...

Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): an on-treatment analysis

Standard

Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): an on-treatment analysis. / Delacrétaz, Etienne; Brenner, Roman; Schaumann, Anselm; Eckardt, Lars; Willems, Stephan; Pitschner, Heinz-Friedrich; Kautzner, Josef; Schumacher, Burghard; Hansen, Peter S; Kuck, Karl-Heinz; VTACH Study Group.

in: J CARDIOVASC ELECTR, Jahrgang 24, Nr. 5, 05.2013, S. 525-529.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Delacrétaz, E, Brenner, R, Schaumann, A, Eckardt, L, Willems, S, Pitschner, H-F, Kautzner, J, Schumacher, B, Hansen, PS, Kuck, K-H & VTACH Study Group 2013, 'Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): an on-treatment analysis', J CARDIOVASC ELECTR, Jg. 24, Nr. 5, S. 525-529. https://doi.org/10.1111/jce.12073

APA

Delacrétaz, E., Brenner, R., Schaumann, A., Eckardt, L., Willems, S., Pitschner, H-F., Kautzner, J., Schumacher, B., Hansen, P. S., Kuck, K-H., & VTACH Study Group (2013). Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): an on-treatment analysis. J CARDIOVASC ELECTR, 24(5), 525-529. https://doi.org/10.1111/jce.12073

Vancouver

Delacrétaz E, Brenner R, Schaumann A, Eckardt L, Willems S, Pitschner H-F et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): an on-treatment analysis. J CARDIOVASC ELECTR. 2013 Mai;24(5):525-529. https://doi.org/10.1111/jce.12073

Bibtex

@article{5f7276ef44544c65990eda779c0206f8,
title = "Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): an on-treatment analysis",
abstract = "BACKGROUND: In the Ventricular Tachycardia Ablation in Coronary Heart Disease (VTACH) study, an intention-to-treat approach was used and may have diminished the observed degree of treatment effect. We present a subanalysis of the VTACH study by treatment actually received.METHODS AND RESULTS: The VTACH study was a prospective, open, randomized controlled trial, undertaken in 16 European centers, comparing defibrillator implantation with and without ventricular tachycardia (VT) ablation in patients with stable VT, previous myocardial infarction, and reduced left-ventricular ejection fraction. Of the 52 patients in the ablation group, 7 (13%) did not receive VT ablation and 19% of patients assigned to implantable cardioverter defibrillator (ICD) only treatment group crossed over and had an ablation. The primary endpoint (first recurrence of any documented VT or ventricular fibrillation [VF]) was reached after a median of 19.5 months in the ablation group and 5.9 months in the ICD only group (P = 0.01). Overall, 685 VT/VF events occurred per year of follow-up in 22 patients of the ablation group and 4,986 events in 43 patients of the control group (P = 0.024). In the ICD only group, median numbers of VT/VF episodes were 25 (IQR 5.8-45.3) and 1.5 (IQR 0-24.8) per patient and year before and after crossover (n = 12), respectively.CONCLUSION: On-treatment analysis of the VTACH study emphasizes the effectiveness of VT ablation in patients receiving ICD treatment because of monomorphic VT post myocardial infarction. VT ablation clearly prolonged time to recurrence of VT/VF episodes and markedly decreased VT/VF burden.",
keywords = "Aged, Catheter Ablation, Defibrillators, Implantable, Female, Humans, Intention to Treat Analysis, Male, Myocardial Infarction/complications, Prospective Studies, Prosthesis Implantation, Stroke Volume, Tachycardia, Ventricular/surgery, Ventricular Fibrillation",
author = "Etienne Delacr{\'e}taz and Roman Brenner and Anselm Schaumann and Lars Eckardt and Stephan Willems and Heinz-Friedrich Pitschner and Josef Kautzner and Burghard Schumacher and Hansen, {Peter S} and Karl-Heinz Kuck and {VTACH Study Group}",
note = "{\textcopyright} 2012 Wiley Periodicals, Inc.",
year = "2013",
month = may,
doi = "10.1111/jce.12073",
language = "English",
volume = "24",
pages = "525--529",
journal = "J CARDIOVASC ELECTR",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): an on-treatment analysis

AU - Delacrétaz, Etienne

AU - Brenner, Roman

AU - Schaumann, Anselm

AU - Eckardt, Lars

AU - Willems, Stephan

AU - Pitschner, Heinz-Friedrich

AU - Kautzner, Josef

AU - Schumacher, Burghard

AU - Hansen, Peter S

AU - Kuck, Karl-Heinz

AU - VTACH Study Group

N1 - © 2012 Wiley Periodicals, Inc.

PY - 2013/5

Y1 - 2013/5

N2 - BACKGROUND: In the Ventricular Tachycardia Ablation in Coronary Heart Disease (VTACH) study, an intention-to-treat approach was used and may have diminished the observed degree of treatment effect. We present a subanalysis of the VTACH study by treatment actually received.METHODS AND RESULTS: The VTACH study was a prospective, open, randomized controlled trial, undertaken in 16 European centers, comparing defibrillator implantation with and without ventricular tachycardia (VT) ablation in patients with stable VT, previous myocardial infarction, and reduced left-ventricular ejection fraction. Of the 52 patients in the ablation group, 7 (13%) did not receive VT ablation and 19% of patients assigned to implantable cardioverter defibrillator (ICD) only treatment group crossed over and had an ablation. The primary endpoint (first recurrence of any documented VT or ventricular fibrillation [VF]) was reached after a median of 19.5 months in the ablation group and 5.9 months in the ICD only group (P = 0.01). Overall, 685 VT/VF events occurred per year of follow-up in 22 patients of the ablation group and 4,986 events in 43 patients of the control group (P = 0.024). In the ICD only group, median numbers of VT/VF episodes were 25 (IQR 5.8-45.3) and 1.5 (IQR 0-24.8) per patient and year before and after crossover (n = 12), respectively.CONCLUSION: On-treatment analysis of the VTACH study emphasizes the effectiveness of VT ablation in patients receiving ICD treatment because of monomorphic VT post myocardial infarction. VT ablation clearly prolonged time to recurrence of VT/VF episodes and markedly decreased VT/VF burden.

AB - BACKGROUND: In the Ventricular Tachycardia Ablation in Coronary Heart Disease (VTACH) study, an intention-to-treat approach was used and may have diminished the observed degree of treatment effect. We present a subanalysis of the VTACH study by treatment actually received.METHODS AND RESULTS: The VTACH study was a prospective, open, randomized controlled trial, undertaken in 16 European centers, comparing defibrillator implantation with and without ventricular tachycardia (VT) ablation in patients with stable VT, previous myocardial infarction, and reduced left-ventricular ejection fraction. Of the 52 patients in the ablation group, 7 (13%) did not receive VT ablation and 19% of patients assigned to implantable cardioverter defibrillator (ICD) only treatment group crossed over and had an ablation. The primary endpoint (first recurrence of any documented VT or ventricular fibrillation [VF]) was reached after a median of 19.5 months in the ablation group and 5.9 months in the ICD only group (P = 0.01). Overall, 685 VT/VF events occurred per year of follow-up in 22 patients of the ablation group and 4,986 events in 43 patients of the control group (P = 0.024). In the ICD only group, median numbers of VT/VF episodes were 25 (IQR 5.8-45.3) and 1.5 (IQR 0-24.8) per patient and year before and after crossover (n = 12), respectively.CONCLUSION: On-treatment analysis of the VTACH study emphasizes the effectiveness of VT ablation in patients receiving ICD treatment because of monomorphic VT post myocardial infarction. VT ablation clearly prolonged time to recurrence of VT/VF episodes and markedly decreased VT/VF burden.

KW - Aged

KW - Catheter Ablation

KW - Defibrillators, Implantable

KW - Female

KW - Humans

KW - Intention to Treat Analysis

KW - Male

KW - Myocardial Infarction/complications

KW - Prospective Studies

KW - Prosthesis Implantation

KW - Stroke Volume

KW - Tachycardia, Ventricular/surgery

KW - Ventricular Fibrillation

U2 - 10.1111/jce.12073

DO - 10.1111/jce.12073

M3 - SCORING: Journal article

C2 - 23350967

VL - 24

SP - 525

EP - 529

JO - J CARDIOVASC ELECTR

JF - J CARDIOVASC ELECTR

SN - 1045-3873

IS - 5

ER -